high density lipoprotein
Small moleculeexperimental
High-density lipoprotein (HDL) is one of the five major groups of lipoproteins. Lipoproteins are complex particles composed of multiple proteins which transport all fat molecules (lipids) around the body within the water outside cells. They are typically composed of 80–100 proteins per particle. HDL particles enlarge while circulating in the blood, aggregating more fat molecules and transporting up to hundreds of fat molecules per particle. — Wikipedia
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2005 (NCT00225719)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaHigh-density lipoprotein ↗
Also known as
- high density lipoprotein
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00395148 | N/A | Mar 1, 2006 | Monash University |
| NCT00822302 | N/A | Feb 1, 2006 | University of London |
| NCT00225719 | Phase 2 | Jul 1, 2005 | CSL, University of Montreal |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CSL | For profit | 1 | 1 | 1 | 2005 |
| Monash University | Academic/Hospital | 1 | 1 | 1 | 2006 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2006 |
| University of Montreal | Academic/Hospital | 1 | 0 | 1 | 2005 |
4 organizations
Page 1 / 1